News Centre
- Global
-
2022-07-22Anti-PD-1 monoclonal antibody Puyouheng (pucotenlimab injection) developed by LEPU BIOPHARMA was approved for marketing
-
2021-08-05The First Domestic TF ADC Drug Approved for Clinical Use: LEPU BIOPHARMA MRG004A
-
2021-07-22MRG003 Hopefully Reshape the Therapeutic Landscape of Advanced NSCLC
-
2021-07-19LEPU BIOPHARMA Conducting a Clinical Trial of MRG002, Bringing New Hopes for HER2-positive Breast Cancer Patients
-
2021-07-15Lepu’s NDA for anti-PD-1 antibody accepted ahead of Hong Kong IPO
-
2021-07-05The NDA for Pucotenlimab (HX008) of LEPU BIOPHARMA as the second-line treatment for melanoma was formally accepted by th
